Edison Talks: Interview with Thomas Meyer, CEO of Auris

Published on 05-08-2019 10:06:57

In this episode of Edison Talks, Edison’s director of research for North America, Maxim Jacobs, has an in-depth discussion with the CEO of Auris Medical, Thomas Meyer. They cover Auris Medical’s development programs for intranasal betahistine for acute vertigo as well as to treat some of the major side effects of antipsychotic medication.

In this episode of Edison Talks, Edison’s director of research for North America, Maxim Jacobs, has an in-depth discussion with the CEO of Auris Medical, Thomas Meyer. They cover Auris Medical’s development programs for intranasal betahistine for acute vertigo as well as to treat some of the major side effects of antipsychotic medication.

01:07 Auris’s AM-125 program for acute vertigo
16:57 The Phase II trial design for AM-125
26:47 AM-201 for antipsychotic-induced weight gain and drowsiness
34:38 The design of the Phase Ib trial for AM-201 and what to expect

Auris Medical Holding – Data coming in second half

Share this with friends and colleagues